JP2021517454A5 - - Google Patents
Info
- Publication number
- JP2021517454A5 JP2021517454A5 JP2020541437A JP2020541437A JP2021517454A5 JP 2021517454 A5 JP2021517454 A5 JP 2021517454A5 JP 2020541437 A JP2020541437 A JP 2020541437A JP 2020541437 A JP2020541437 A JP 2020541437A JP 2021517454 A5 JP2021517454 A5 JP 2021517454A5
- Authority
- JP
- Japan
- Prior art keywords
- immune cells
- arginase
- cells
- immune
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18153782 | 2018-01-28 | ||
| EP18153782.0 | 2018-01-28 | ||
| PCT/EP2019/051806 WO2019145453A1 (en) | 2018-01-28 | 2019-01-24 | Arginase suppression for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517454A JP2021517454A (ja) | 2021-07-26 |
| JP2021517454A5 true JP2021517454A5 (cg-RX-API-DMAC7.html) | 2022-02-24 |
Family
ID=61074351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541437A Pending JP2021517454A (ja) | 2018-01-28 | 2019-01-24 | 癌治療のためのアルギナーゼ抑制 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210177897A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3743510A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021517454A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111902532A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019211067A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3125797A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019145453A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| AU2019246728A1 (en) | 2018-03-29 | 2020-08-27 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| GB201912030D0 (en) * | 2019-08-21 | 2019-10-02 | Cancer Research Tech Ltd | Binding molecules |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2431080A1 (en) * | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| WO2007111626A2 (en) | 2006-03-23 | 2007-10-04 | The Johns Hopkins University | Arginase ii: a target for the prevention and treatment of atherosclerosis |
| MX2009005370A (es) | 2006-11-21 | 2009-10-16 | Univ Groningen | Uso de inhibidores de arginasa en el tratamiento de asma y rinitis alergica. |
| CA2852685C (en) | 2011-10-19 | 2019-02-26 | Mars, Incorporated | Inhibitors of arginase and their therapeutic application |
| WO2014059248A1 (en) * | 2012-10-12 | 2014-04-17 | Philadelphia Health & Education Corporation D/B/A/ Drexel | Mir-155 enhancement of cd8+ t cell immunity |
| WO2014066137A1 (en) * | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
| EP3137103B1 (en) | 2014-04-29 | 2021-10-20 | Bio-Cancer Treatment International Ltd. | Methods and compositions for modulating the immune system with arginase i |
| WO2016187459A1 (en) | 2015-05-20 | 2016-11-24 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| KR102929174B1 (ko) | 2015-10-30 | 2026-02-20 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법 |
| US11291674B2 (en) * | 2016-11-08 | 2022-04-05 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
-
2019
- 2019-01-24 EP EP19705288.9A patent/EP3743510A1/en not_active Withdrawn
- 2019-01-24 WO PCT/EP2019/051806 patent/WO2019145453A1/en not_active Ceased
- 2019-01-24 AU AU2019211067A patent/AU2019211067A1/en not_active Abandoned
- 2019-01-24 JP JP2020541437A patent/JP2021517454A/ja active Pending
- 2019-01-24 US US16/963,380 patent/US20210177897A1/en not_active Abandoned
- 2019-01-24 CN CN201980021913.2A patent/CN111902532A/zh active Pending
- 2019-01-24 CA CA3125797A patent/CA3125797A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | From concept to cure: The evolution of CAR-T cell therapy | |
| Rui et al. | Cancer immunotherapies: advances and bottlenecks | |
| JP7755890B2 (ja) | Car発現ベクター及びcar発現t細胞 | |
| US20260055157A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| US20210338729A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF | |
| JP2024008968A (ja) | 複数の抗原を標的とするcompoundキメラ抗原受容体(cCAR)の組成物およびその使用方法 | |
| CN114761037A (zh) | 结合bcma和cd19的嵌合抗原受体及其用途 | |
| Iwamura et al. | siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions | |
| US20190255108A1 (en) | Chimeric antigen receptor (car) targeting multiple antigens, compositions and methods of use thereof | |
| US20210069241A1 (en) | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression | |
| Testa et al. | CAR-T cell therapy in B-cell acute lymphoblastic leukemia | |
| EP3490590A2 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| Hu et al. | Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer | |
| KR20200137030A (ko) | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 | |
| CN106574272A (zh) | 靶向多样的多种抗原的通用嵌合抗原受体表达性免疫细胞及其制造方法及其在癌症、感染和自身免疫病的治疗中的应用 | |
| US20230226181A1 (en) | GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY | |
| WO2022037562A1 (en) | Engineered immunoresponsive cells and uses thereof | |
| Chen et al. | Natural killer cells: the next wave in cancer immunotherapy | |
| Yu et al. | Revolution of CAR engineering for next-generation immunotherapy in solid tumors | |
| JP2025518033A (ja) | 免疫細胞クリスパースクリーニングのための方法及び組成物 | |
| JP2025513626A (ja) | Ciita遺伝子がノックアウトされた操作された免疫細胞及びその用途 | |
| Chen et al. | Innovative gene engineering strategies to address tumor antigen escape in cell therapy | |
| Cortés-Hernández et al. | Chimeric antigen receptor (CAR) T cell therapy for cancer. Challenges and opportunities: An overview | |
| KR20260070126A (ko) | Car t 세포의 기능성을 향상시키기 위한 il-2 변이체를 함유하는 car-인게이저 |